PLOS ONE:不同射程分数的心力衰竭患者的生活质量如何?

2019-06-29 海北 MedSci原创

已有的指南根据左心室射血分数(LVEF)将患有心力衰竭(HF)的患者分为3个不同的组。最近,研究人员使用明尼苏达生活心力衰竭问卷(MLHFQ)来量化HF患者的健康相关生活质量。 在该研究中,患者被分为三组:保留LVEF(> 50%),中位LVEF(40-49%),和降低LVEF(<40%)。研究人员使用单向ANOVA评估MLHFQ评分,并且在组之间观察差异。通过Spearman相关分

已有的指南根据左心室射血分数(LVEF)将患有心力衰竭(HF)的患者分为3个不同的组。最近,研究人员使用明尼苏达生活心力衰竭问卷(MLHFQ)来量化HF患者的健康相关生活质量。

在该研究中,患者被分为三组:保留LVEF> 50%),中位LVEF40-49%),和降低LVEF<40%)。研究人员使用单向ANOVA评估MLHFQ评分,并且在组之间观察差异。通过Spearman相关分析分析纽约心脏协会(NYHA)类与身体评分的关联。使用Kaplan-Meier曲线评估死亡和HF相关住院治疗的总MLHFQ评分的预测效用。 Cox比例风险模型用于确定预后的风险因素。用Cronbachα评估内部可靠性。

结果显示,三组总MLHFQ评分和MLHFQ分量表评分存在显着差异(p <0.05)。 MLHFQ结构域在三组之间表现出高内部一致性(Cronbachα= 0.92,0.960.93)。 MLHFQ物理量表评分与HFrEFr = 0.59p <0.001)和HFmrEF患者(r = 0.537p <0.001)中的NYHA分级显着相关。

生存分析表明,考虑高评分的MLHFQ,三组间有显着性差异(p = 0.038)。在具有低MLHFQ评分的组中,与HFpEF组相比,HFmrEF组显示出显着增加的死亡率和HF相关住院率(p = 0.035)。

因此,不同EF值的心力衰竭患者的特征和临床结果各不相同。 MLHFQ似乎是一种有效和可靠的健康状况测量,并提供良好的预后能力。


原始出处:

Chen X et al. Quality of life and outcomes in heart failure patients with ejection fractions in different ranges. PLOS ONE, 2019; doi: 10.1371/journal.pone.0218983. eCollection 2019.


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1790349, encodeId=e2801e90349c2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Dec 16 14:35:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368799, encodeId=46c5368e99a2, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Mon Jul 01 23:56:40 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368674, encodeId=00c33686e442, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/20/db9fdbf4704eb33e2c8baa227441bd0b.jpg, createdBy=69ec2342118, createdName=戒律, createdTime=Sun Jun 30 17:31:40 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368625, encodeId=ca5b368625af, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/2EVCwc9WmQS6ec99H2TX8ejmR40xYjwrIcrqjAnibV36aicL1sLxc21rhpZnqTOxk33HP44iayEwo6qYXqgZvdRtA/132, createdBy=d0d01573846, createdName=329523732, createdTime=Sat Jun 29 22:14:26 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1790349, encodeId=e2801e90349c2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Dec 16 14:35:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368799, encodeId=46c5368e99a2, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Mon Jul 01 23:56:40 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368674, encodeId=00c33686e442, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/20/db9fdbf4704eb33e2c8baa227441bd0b.jpg, createdBy=69ec2342118, createdName=戒律, createdTime=Sun Jun 30 17:31:40 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368625, encodeId=ca5b368625af, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/2EVCwc9WmQS6ec99H2TX8ejmR40xYjwrIcrqjAnibV36aicL1sLxc21rhpZnqTOxk33HP44iayEwo6qYXqgZvdRtA/132, createdBy=d0d01573846, createdName=329523732, createdTime=Sat Jun 29 22:14:26 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
    2019-07-01 1de48adem68(暂无匿称)

    不错

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1790349, encodeId=e2801e90349c2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Dec 16 14:35:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368799, encodeId=46c5368e99a2, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Mon Jul 01 23:56:40 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368674, encodeId=00c33686e442, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/20/db9fdbf4704eb33e2c8baa227441bd0b.jpg, createdBy=69ec2342118, createdName=戒律, createdTime=Sun Jun 30 17:31:40 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368625, encodeId=ca5b368625af, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/2EVCwc9WmQS6ec99H2TX8ejmR40xYjwrIcrqjAnibV36aicL1sLxc21rhpZnqTOxk33HP44iayEwo6qYXqgZvdRtA/132, createdBy=d0d01573846, createdName=329523732, createdTime=Sat Jun 29 22:14:26 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
    2019-06-30 戒律

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1790349, encodeId=e2801e90349c2, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Mon Dec 16 14:35:00 CST 2019, time=2019-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368799, encodeId=46c5368e99a2, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Mon Jul 01 23:56:40 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368674, encodeId=00c33686e442, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/07/20/db9fdbf4704eb33e2c8baa227441bd0b.jpg, createdBy=69ec2342118, createdName=戒律, createdTime=Sun Jun 30 17:31:40 CST 2019, time=2019-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368625, encodeId=ca5b368625af, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/2EVCwc9WmQS6ec99H2TX8ejmR40xYjwrIcrqjAnibV36aicL1sLxc21rhpZnqTOxk33HP44iayEwo6qYXqgZvdRtA/132, createdBy=d0d01573846, createdName=329523732, createdTime=Sat Jun 29 22:14:26 CST 2019, time=2019-06-29, status=1, ipAttribution=)]
    2019-06-29 329523732

    不错

    0

相关资讯

Int J Cardiol:代谢参数变异性与心力衰竭风险

由此可见,BP、BMI、FBG和TC的高度变异性与新发HF的发生率较高有协同作用。

CTSC2019丨2018中国心力衰竭指南更新亮点

编者按:近年来,心力衰竭(HF)发病越来越多,已成为亟待解决的、影响公众健康的最严重公共卫生问题之一,其诊治备受关注。因此,HF诊断与治疗的相关研究不断开展,相关指南不断更新。在第十届国际心血管疾病药物治疗高峰论坛(10thCTSC)基础医学论坛上,来自首都医科大学附属北京安贞医院的胡荣教授就2018年中国最新发布的HF指南(简称新指南)更新亮点作了专题解读。

Int J Cardiol:美国心力衰竭诊断年龄的差异和驱动因素

由此可见,美国HF诊断的中位年龄为59岁。生活贫困、缺乏健康保险和肥胖的NH黑人是美国早期诊断HF的主要驱动因素。

CTSC2019丨丁荣晶教授:心力衰竭患者I期和居家心脏康复病例分享

编者按:心脏康复已成为心血管疾病管理的重要内容,有助于使患者获益最大化。2019年6月6日,在第十届国际心血管疾病药物治疗高峰论坛(10thCTSC)临床心脏运动康复专场上,来自北京大学人民医院的丁荣晶教授结合形象的实践病例就如何对心力衰竭(HF)患者I期及居家进行心脏康复作了专题解析。

CIHFC2019丨心力衰竭生物标志物研究现状与进展

编者按:临床实践中,心力衰竭(HF)的诊断及预后预测都离不开生物标志物所提供的重要讯息。那么,心力衰竭生物标志物领域近年来取得哪些研究进展?我们应如何利用好传统及新型生物标志物进行心力衰竭的诊断、预后预测甚至是指导治疗?6月21日,在CIHFC 2019年会上,河北医科大学第二医院李拥军教授从心力衰竭的病理生理机制入手,解析心力衰竭生物标志物研究现状及进展。

2019中国国际心力衰竭大会暨中国医师协会心力衰竭专业委员会第四届年会、国家心力衰竭医联体和国家心力衰竭专业质控大会在京隆重召开

心力衰竭是危害全民健康的最重要的心血管疾病之一,心力衰竭领域也是当今心血管最受关注的热点之一。为进一步推动心力衰竭的学术交流、加强心力衰竭及相关疾病的医生培训,促进心力衰竭国际最新研究和学术进展的国内传播。2019年6月22日上午,由国家心血管病中心、中国医师协会、中国医师协会心力衰竭专业委员会、中国医学科学院阜外医院、北京力生心血管健康基金会联合主办、《中华心力衰竭和心肌病杂志》协办的“20